Hagens Berman Sobol Shapiro LLP

San Francisco – September 10, 2026 -- Hagens Berman Sobol Shapiro LLP has filed a securities class action against Regeneron Pharmaceuticals (NASDAQ: REGN) after the failure of a Phase 3 melanoma trial wiped out $11 billion in market capitalization. The suit covers investors who purchased Regeneron shares between August 1, 2025, and May 15, 2026, with a lead plaintiff deadline set for September 14, 2026.

Regeneron's Fianlimab-Libtayo combination failed to hit its primary endpoint

The complaint centers on Regeneron's Phase 3 trial testing Fianlimab combined with Libtayo as a first-line treatment for metastatic or locally advanced melanoma, a therapy management repeatedly called a "potential blockbuster." On May 15, 2026, Regeneron disclosed the trial did not reach statistical significance on its primary endpoint of progression-free survival.

San Francisco – September 10, 2026 -- A securities class action has been filed against PROCEPT BioRobotics Corporation (NASDAQ: PRCT), alleging the company inflated handpiece sales through an undisclosed bulk-discount program that pulled forward demand and masked deteriorating customer inventory levels. Law firm Hagens Berman Sobol Shapiro LLP is representing investors who purchased PROCEPT stock between February 28, 2024 and February 25, 2026, with a lead plaintiff deadline set for September 22, 2026.

San Francisco – September 10, 2026 -- Hagens Berman Sobol Shapiro LLP has filed a securities class action against Cogent Communications Holdings (NASDAQ: CCOI), alleging the company misrepresented its optical wavelength "backlog" as a reliable indicator of revenue growth between February 29, 2024 and May 1, 2026.

Lawsuit targets Cogent's wavelength backlog disclosures as misleading investors

The complaint alleges Cogent's wavelength backlog was largely illusory, with customers unable or unwilling to accept delivery even when the company could provision the wavelengths. Plaintiffs claim this misrepresented actual customer demand and inflated the company's growth narrative.

San Francisco – September 10, 2026 -- Wix.com Ltd. (NASDAQ: WIX) is now the target of a securities class action following a 27% plunge in its share price after the company disclosed Q1 2026 results showing operating expenses had spiked 46% year-over-year. The case, Yappi v. Wix.com Ltd., et al., No. 26-cv-08852, was filed in the U.S. District Court for the Northern District of Illinois and seeks to represent investors who bought Wix securities between February 19, 2025 and May 12, 2026.

San Francisco – September 10, 2026 -- Investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) have until September 28, 2026, to seek lead plaintiff status in a securities class action tied to the company's Duchenne muscular dystrophy therapy, deramiocel, as the FDA extends its review timeline.

FDA pushes deramiocel decision to November 22, 2026

On August 24, 2026, Capricor disclosed that the FDA extended the PDUFA target action date for its lead cell therapy deramiocel from August 22, 2026, to November 22, 2026. The agency classified the company's post-Advisory Committee submission as a major amendment, which included 24-month open-label extension data from the Phase 3 HOPE-3 study and a bid to narrow the therapy's indication to upper limb function.

SAN FRANCISCO – September 10, 2026 -- Hagens Berman Sobol Shapiro LLP has expanded a securities fraud class action against Pentair plc (NYSE: PNR), extending the class period back to March 11, 2025, from the original start date of April 28, 2026. The lead plaintiff deadline is set for October 2, 2026, giving investors who purchased Pentair stock during the newly expanded window until that date to seek appointment as lead plaintiff.

Lawsuit alleges Pentair concealed severe Pool segment channel destocking

The amended complaint alleges Pentair and top executives made materially false and misleading statements about the company's financial health, channel inventory and internal controls beginning March 11, 2025. Plaintiffs claim Pentair failed to disclose undisclosed channel-loading practices with distributors designed to artificially inflate short-term financial metrics, particularly within its core Pool segment.

San Francisco – September 10, 2026 -- Hagens Berman Sobol Shapiro LLP has filed a securities fraud class action against Alibaba Group Holding Limited (NYSE: BABA), alleging the company concealed ties to China's Ministry of Industry and Information Technology (MIIT) and engaged in unauthorized AI model theft. The case, Wistisen v. Alibaba Group Holding Limited, et al., No. 1:26-cv-06654, is filed in the U.S. District Court for the Southern District of New York.

San Francisco – September 10, 2026 -- Hagens Berman Sobol Shapiro LLP has opened an investigation into Aardvark Therapeutics, Inc. (NASDAQ: AARD) over allegations that the company misled investors about the safety of its lead drug candidate ARD-101, ahead of an October 13, 2026 deadline for shareholders to seek lead plaintiff status in a pending securities class action.

Investors who bought Aardvark stock between February 13, 2025 and May 14, 2026 are covered by the class period

The lawsuit targets purchasers who acquired shares pursuant to Aardvark's February 13, 2025 initial public offering, as well as those who bought securities through May 14, 2026. The complaint alleges the company's offering documents failed to disclose that ARD-101 was significantly less safe than represented, including reversible cardiac observations such as QRS prolongation at above-target doses during clinical trials.

San Francisco – September 10, 2026 -- Hims & Hers Health, Inc. (NYSE: HIMS) and certain executives now face a securities class action after a July 29, 2026 federal complaint from the Federal Trade Commission wiped over $970 million from the company's market capitalization in a single trading session, sending shares down $4.32, or 14.7%.

FTC alleges Hims shared health data with Meta and Snap despite privacy pledges

The FTC complaint, filed alongside co-plaintiffs the State of Utah and Los Angeles County representing California, accuses Hims of surreptitiously sharing sensitive user medical conditions and personal health data with third-party advertising platforms including Meta Platforms and Snap. Regulators allege the company used embedded tracking pixels and customer list matching to transmit this data, contradicting public assurances that it maintained administrative, physical, and technical safeguards for health and personal information.